<DOC>
	<DOCNO>NCT02965781</DOCNO>
	<brief_summary>This study evaluate safety efficacy SADBE prevention recurrent herpes labialis adult . Two-thirds participant receive SADBE solution , third receive vehicle placebo control . The solution administer topically patient 's arm . The study compare single-arm application versus two-arm application versus two placebo dos arm .</brief_summary>
	<brief_title>Double-blind , Vehicle-controlled Study Efficacy Safety SADBE Subjects With Recurrent Herpes Labialis</brief_title>
	<detailed_description />
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Squaric acid dibutyl ester</mesh_term>
	<criteria>Age â‰¥18 Clinical diagnosis herpes labialis , may make screen visit base patient 's selfreported history symptom . An active herpes labialis outbreak time entry clinical trial neither require exclusion criterion . Self report four episode herpes labialis past 12 month People treatment anti viral therapy within 2 week sensitization dose . Pregnant lactating female . Current recurrent nonherpetic infection underlie condition may predispose infection anyone admit hospital due bacteremia , pneumonia serious infection . Therapy glucocorticoid immunosuppressant time recruitment within past 4 week , except inhaled corticosteroid asthma topical steroid sit face . History malignancy ( except patient surgically cure basal cell squamous cell skin cancer ) History organ transplantation HIVpositive status determine history screen know history immunosuppressive disease . Severe comorbidities ( diabetes mellitus require insulin , CHF ( EF &lt; 50 % baseline exclusionary ) MI , CVA TIA within 3 month screen visit , unstable angina pectoris , oxygendependent severe pulmonary disease History exposure squaric acid squaric acid dibutyl ester . Known hypersensitivity DMSO Any condition judge investigator cause clinical trial detrimental patient . Subject currently enrol another investigational device drug trial ( ) , subject receive investigational agent ( ) within 28 day baseline visit . Previous current participation clinical trial SADBE treat herpes labialis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>